Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends-Reference-Cited by-同舟云学术

Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends

Published:2017-03-09 Issue:4 Volume:10 Page:345-364
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Stahl Maximilian¹,Zeidan Amer M.¹

Affiliation:

1. Section of Hematology, Department of Internal Medicine, Section of Hematology, Yale University and the Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, USA

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2017.1297704

Reference234 articles.

1. Myelodysplastic Syndromes

2. Recent developments in myelodysplastic syndromes

3. Current therapy of myelodysplastic syndromes

4. Incidence and Burden of the Myelodysplastic Syndromes

5. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A new therapeutic perspective: Erastin inhibits tumor progression by driving ferroptosis in myelodysplastic syndromes;Journal of Investigative Medicine;2024-05-11

2. Therapeutic strategies in low and high-risk MDS: What does the future have to offer?;Blood Reviews;2021-01

3. Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options;Cancer Management and Research;2021-01

4. Emerging treatment options for patients with high-risk myelodysplastic syndrome;Therapeutic Advances in Hematology;2020-01

5. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis;Leukemia & Lymphoma;2019-06-07